Abstract: Disclosed are methods of and systems for creating an anti reflection structure surface (ARSS) on a fiber optic tip, as well as fiber optic tips themselves. A representative method can comprise providing a fiber optic having a first tip at a first end of the fiber optic and a second tip at a second end of the fiber optic opposite the first end of the fiber optic, each of the first and second tip having an end face; disposing a layer of masking material on a surface of the end face of one of the fiber optic tips; exposing the layer of masking material to a laser to form one or more metal islands of the surface of the fiber optic tip; and etching the surface to provide one or more anti reflection structures on the surface of the fiber optic tip.

Abstract: A method for producing an image of a vessel with ultrasound includes administering a contrast agent particle into the vessel and delivering an ultrasound pulse having a first frequency range to the vessel. The method further includes detecting ultrasound energy scattered from the contrast agent particle at a second frequency range, converting the scattered ultrasound energy into an electronic radio frequency signal, and using an algorithm to determine a spatial location of the contrast agent particle based on extraction of a specific feature of the radio frequency signal. The method further includes generating an image by displaying a marker of the spatial location of the contrast agent particle with a resolution that is finer than a pulse length of the ultrasound pulse and repeating the steps for different contrast agent particles until sufficient markers have been accumulated to reconstruct a pattern of the vessel.

Abstract: Methods for imaging a sample using fluorescence microscopy, systems for imaging a sample using fluorescence microscopy, and illumination systems for fluorescence microscopes. In some examples, a method includes positioning the sample such that a plane of interest of the sample is coplanar with a focal plane of a detection objective of a microscope; positioning a mirror around the sample; directing a beam of annularly collimated excitation light on the mirror to focus a disc of light on the sample; and imaging the sample through the detection objective.

Abstract: The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.

Abstract: Decoding methods are provided for identifying populations in assays, particularly multiplexing assays and those associated with fluidic devices.

Abstract: Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.

Abstract: Methods and compositions are provided for determining a subtype of lung adenocarcinoma (AD) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung adenocarcinoma. Also provided herein are methods and compositions for determining the response of an individual with an adenocarcinoma subtype to a therapy such as immunotherapy.

Abstract: In one aspect, separation media are described herein operable for removing one or more water contaminants, including NOM, fluorinated chemicals, and/or derivatives thereof. Briefly, a separation medium comprises a silica-containing granular support; and an oligomeric stationary phase forming a film on individual grains of the granular support. In some embodiments, the oligomeric stationary phase comprises oligomeric chains covalently bound to the individual grains.

Abstract: The present disclosure is directed to double junction tandem perovskite solar cells having a n+/n interconnection layer comprising an ion-doped fullerene layer and a metal oxide layer. In certain embodiments, the metal oxide is SnO2-x (0<x<1). The ion-doped fullerene and metal oxide layers form Ohmic contacts with the wide bandgap and narrow bandgap perovskite sub cells and demonstrate low resistivity and high power conversion efficiencies.

Abstract: The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to Factor VIII proteins containing modifications in the amino acid sequence of the Factor VIII protein, as well as nucleic acid constructs encoding the Factor VIII proteins and methods of using these compositions to treat a bleeding disorder.

Abstract: Compositions, devices, kits and methods are disclosed for assaying triglyceride with a glycerol 3-phosphate oxidase mutant. The glycerol 3-phosphate oxidase mutant has reduced oxidase activity while substantially maintaining, or increasing, its dehydrogenase activity, compared to the wild-type glycerol 3-phosphate oxidase.

Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.

Abstract: The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

Abstract: The presently disclosed subject matter relates generally to a highly ionically conductive solid electrolyte membrane and to batteries comprising such solid electrolyte membrane.

Abstract: Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.

Abstract: Disclosed herein are devices, apparatuses and methods for generating self-sustaining gaseous and non-gaseous gradients across a cell support structure and for culturing one or more cells or tissues under hypoxic conditions. Methods of generating one or more gas gradients across a cell support structure include providing a luminal container having a bottom wall that is a gas permeable membrane, positioning a cell support structure above the bottom wall, positioning one or more cells or tissues on the cell support structure, and generating one or more gas gradients between the bottom wall, across the cell support structure and into a luminal reservoir. An apparatus to produce hypoxic conditions for cell cultures includes a luminal container having a bottom wall, a cell support structure on the bottom wall, and a cover that sealably closes the open top, such that a hypoxic condition can be generated in the luminal reservoir.

Abstract: Analysis systems with a housing having a chamber sized and configured to receive at least one microfluidic device. The systems also include an optic system coupled to the housing in optical communication with the at least one microfluidic device, a controller coupled to the optic system, a heat source coupled to the optic system and thermally coupled to the at least one microfluidic device held in the housing, and a sub-array selection module in communication with the controller. The sub-array selection module is configured to select a sub-set of sets of microwells of at least one fluid channel of the microfluidic device for imaging by the optic system after a reaction step (e.g., one thermocycle) during an assay.

Abstract: A microfluidic device includes a plurality of reaction wells; and a plurality of solid supports, and each of the solid supports has a reagent attached thereto. The reagent is attached to the solid support via a labile reagent/support bond such that the reagent is configured to be cleaved from the support via a cleaving operation.

Abstract: The present invention is directed to the use of (1) mucin concentration in sputum; (2) individual airway mucins MUC5AC and MUC5B ratio (MUC5AC/MUC5B) in sputum; and (3) combination of both measurements (Kesimer MUCQuant index) that can be used as an objective biomarker for differential diagnosis of smoking status and chronic bronchitis (CB), disease severity of CB (mild, moderate, and severe), exacerbation status, monitoring progression of CB, and guiding of therapies for CB. In addition, the ratio of amount of IgGFc-binding protein (FCGBP) and the amount of bactericidal/permeability-increasing fold-containing family member A1 (BPIFA1 (or SPLUNC1)) present in a sputum sample from a subject may be used in combination with the Kesimer MUCQuant index (Kesimer MUCQuant Plus index) for differential diagnosis of smoking status and CB, disease severity of CB, exacerbation status, p monitoring progression of CB, and guiding of therapies for CB.

Abstract: The invention relates to chimeric AAV capsids targeted to oligodendrocytes and virus vectors comprising the same. The invention further relates to methods of delivering a nucleic acid of interest to an oligodendrocyte in vitro and in vivo, methods of delivering a nucleic acid of interest to an area of the CNS bordering a compromised blood-brain barrier, and methods of treating disorders associated with oligodendrocyte dysfunction using the AAV capsids and virus vectors of the invention.